NCT00659594

Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray (200 mg, Once Daily), in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 18 Years and Older

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 500 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this placebo-controlled EEC study is to determine the time to onset of action of ciclesonide, applied as a nasal spray (200 mg, once daily) in patients with SAR.

Conditions

• Rhinitis, Allergic, Seasonal
• Hay Fever

Interventions

Type	Name	Description
DRUG	Ciclesonide	200µg Ciclesonide versus Placebo
DRUG	Placebo	placebo

Timeline

• Start date: 2004-11-01
• Primary completion: 2005-02-01
• Completion: 2005-09-01
• First posted: 2008-04-16
• Last updated: 2016-12-02

Locations

1 site across 1 country: Canada